肺癌靶向治疗药物EGFR-TKIs与其心脏毒性的研究进展

靶向药物治疗的问世极大地改变了晚期非小细胞肺癌的治疗格局,但靶向药物抗癌治疗的心脏毒性副作用严重影响非小细胞肺癌的预后,甚至成为了癌症患者第二大死亡原因。因此,早期识别靶向药物心脏毒性副作用,对心血管疾病的预防及治疗至关重要。现探讨新型靶向药物表皮生长因子受体抑制剂可能引起的心脏毒性副作用,包括血栓栓塞事件、心力衰竭、心肌病、心律失常及高血压等,并总结其各自的心血管不良反应机制,对晚期肺癌患者的心脏管理提供有益的建议,最大限度地提高肺癌幸存者的治疗效果。

EGFR-TKIs and Its Cardiotoxicity in Lung Cancer

The advent of targeted drug therapy has greatly changed the treatment pattern of advanced non-small cell lung cancer(NSCLC) and become a good news for lung cancer patients.However, the cardiotoxic side effects of targeted drug therapy seriously affect the prognosis of NSCLC and even become the second leading cause of death in cancer patients.Therefore, early identification of cardiotoxicity of targeted drugs is crucial for the prevention and treatment of cardiovascular diseases.This review aims to explore the potential cardiotoxic side effects caused by novel targeted drugs—epidermal growth factor receptor inhibitors, including thromboembolic events, heart failure, cardiomyopathy, arrhythmia, hypertension, etc.In addition, the mechanisms of cardiovascular adverse reactions are summarized to provide useful suggestions for cardiac management of patients with advanced lung cancer and maximize the therapeutic effect of lung cancer survivors.